Cocaine-Methylphendidate Interaction Study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cincinnati,
Ohio45220

Purpose:

The purpose of this study is to attempt to identify possible dangerous interactions between
cocaine and methylphenidate (MPD). Additional objectives are to determine: a) if MPD reduces
the craving and high for cocaine; b) if there are pharmacokinetic and pharmacodynamic
interactions between cocaine and MPD; and c) the relationship between cocaine and
benzoylecgonine (BE) levels in plasma and BE levels in urine.

Study summary:

This study was conducted to evaluate the cardiovascular risk of prescribing up to 90 mg of
methylphenidate (MPD) daily for treating cocaine dependence. This within-subject study was
completed in an inpatient setting. It was non-blinded for MPD dose and single-blinded for
cocaine dose. Each patient was given intravenous cocaine at 0, 20 and 40 mg while at three
different steady state levels of MPD (0, 60 and 90 mg). Seven non-treatment seeking cocaine
addicts, who were recruited from the community, completed the study. There were no cardiac
rhythm abnormalities noted except for sinus tachycardia and sinus bradycardia. There were no
incidences of seizures or myocardial ischemia. In a repeated measures ANOVA, MPD was shown
to have an independent positive effect on heart rate (p=0.0001) but not on SBP or DBP. There
was no cocaine by MPD interaction for any vital sign. Peak systolic blood pressure (SBP) and
diastolic blood pressure (DBP) for any patient up to 60 minutes after infusion was 169 mm
and 108 mm, respectively. The first occurred when 60 mg of MPD and placebo cocaine were
given and the second when no MPD and placebo cocaine were given. Peak heart rate for any
patient up to 60 min after infusion was 143/min at 60 mg of MPD and 40mg of cocaine. The
number of adverse events reported when cocaine and MPD were given together was less than the
number reported when either drug was given alone. The adverse events reported when cocaine
and MPD were given together included headache, nervousness, and lightheadedness. Subjective
ratings of drug effect revealed that MPD did not enhance patients' response to, or desire
for, cocaine. MPD appears to be a safe drug to use in cocaine addicts who continue to use
cocaine at the dosages tested.

Criteria:

Inclusion Criteria:
1. male or female of any race, between 21 and 45 years of age.
2. cocaine dependent according to DSM-IV criteria.
3. currently use cocaine by smoked or intravenous route of administration and confirmed
by positive urine screen for benzoylecgonine within 2 weeks prior to signing the
informed consent form. The subjects who currently use cocaine by smoked route must
have a history of intravenous exposure to drugs of abuse.
4. in stable physical and mental health as judged by interview and physical
examinations.
5. for female subjects, test non-pregnant and use adequate birth control. All female
subjects will have a serum pregnancy test performed prior to the first dose of study
medication.
6. be capable of providing written informed consent to participate in this study.
7. able to comply with protocol requirements and be likely to complete all study
treatments.
8. within 20% of ideal body weight.
Exclusion Criteria:
1. require detoxification from alcohol, opiates, or sedative-hypnotics.
2. have a history of significant hepatic, renal, endocrine, cardiac (i.e., arrhythmia
requiring medication, angina pectoris, myocardial infarction), stroke, seizure,
neurological, non-drug-related psychiatric, gastrointestinal, pulmonary,
hematological or metabolic disorders.
3. have a history of adverse reaction to cocaine including loss of consciousness, chest
pain, psychosis, or seizure.
4. have a history of adverse reaction/hypersensitivity to methylphenidate.
5. test positive upon urine toxicology screen for opiates, benzodiazepines, barbiturates
or related CNS depressants, amphetamines or related stimulants.
6. have clinically significant abnormal laboratory measurements in liver function tests
(AST and ALT levels greater than 3 times of the upper limit of normal), hematology
(CBC, differential, platelet count), serum chemistries (SMA-24) and EKG.
7. have any significant active medical, or psychiatric illness which might inhibit their
ability to complete the study or might be complicated by administration of the test
drug.
8. have active hypertension as defined by the American Heart Association criteria.
9. currently receive any medications for the treatment of any significant medical
conditions.
10. have a history of glaucoma.
11. have a diagnosis or family history of Tourettes syndrome.
12. have an abnormal thyroid function (as determined by an abnormal T4 level).
13. have a history of seizures or seizure disorder.
14. have any medical history or condition considered by the investigator(s) to place the
subjects at increased risk.

NCT ID:

NCT00015067

Primary Contact:

Principal InvestigatorEugene Somoza, M.D., Ph.D.Cincinnati MDRU

Backup Contact:

N/A

Location Contact:

Cincinnati, Ohio 45220United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.